奥沙利铂联合吡柔比星和氟尿嘧啶治疗晚期肝癌的临床疗效分析  

Efficacy of oxaliplatin combined with pirarubicin and 5-fluorouracil for advanced hepatocellular carcinoma

作　　者：谢勋鹏[1] 陈萍[1] 张莉莉[1] 朱红军[1] 陆宏宾[1] 

机构地区：[1]南通大学附属第三医院肿瘤科,江苏南通226000

出　　处：《现代肿瘤医学》2012年第10期2138-2140,共3页Journal of Modern Oncology

摘　　要：目的:探讨联合化疗方案治疗晚期原发性肝癌患者的有效性与安全性。方法:31例晚期原发性肝癌患者,采用奥沙利铂(L-OHP)、吡柔比星(THP)、氟尿嘧啶(5-FU)组成的联合方案进行化疗,观察和评价其疗效及毒副反应。结果:31例患者中,获得CR 0例,PR 9例,SD 14例,PD 8例,疾病控制率(DCR)74.2%;中位肿瘤进展时间(TTP)4.2月;中位生存期(OS)为10.2月;临床受益反应(CBR)率达77.4%;化疗后的血清AFP值较前明显下降。主要的毒副反应为骨髓抑制、消化道反应和感觉神经毒性。结论:奥沙利铂、吡柔比星、氟尿嘧啶组成的联合方案治疗晚期原发性肝癌的疗效安全可靠,不良反应可以接受。Objective：To assess the efficiency and safety of systemic chemotherapy in the patients with histologically confirmed recurrent,metastatic,or unresectable hepatocellular carcinoma（HCC）.Methods：Thirty one patients with advanced HCC were given systemic chemotherapy（THP 35mg/m2 iv d1;L-OHP 100-130mg/m2 ivgtt d1;CF 200mg/m2 ivgtt d1-2;5-FU 400mg/m2 iv d1-2,600mg/m2 civ 22h d1-2;or CF 400mg/m2 ivgtt d1;5-FU 400mg/m2 iv d1,2400mg/m2 civ 46h,repeated every 3-4 weeks）.Tumor response,time to progression,survival,and toxicity were evaluated.Results：None of the patients had a complete response to treatment,9 patients obtained partial response,14 patients stable disease,8 patients disease progression;Median time to tumor progression（TTP） was 4.2 months,median overall survival（OS） 10.2 months.Compared to pre-treatment,there was a significant decrease of serum AFP level.The main toxic side effects included hematologic toxicity,alimentray tract reaction and neurotoxicity.Conclusion：The systemic chemotherapy regimen combined L-OHP,THP and 5-FU is a safe and effective therapy for patients with advanced HCC.All the adverse effects were well tolerable.

关 键 词：原发性肝癌 奥沙利铂 吡柔比星 氟尿嘧啶 全身化疗 

分 类 号：R735.7[医药卫生—肿瘤]